Planet Labs Beats Q2, Raises FY27 Guidance, But Stock Dips on Continued Skepticism

What happened

Planet Labs reported fiscal Q2 2027 earnings that exceeded expectations, with revenue above analyst estimates and full-year guidance raised to $430M–$441M. Despite the beat, the stock fell about 1% as analysts issued mixed notes, likely reflecting ongoing worries about backlog quality, dilution from the $1.5B ATM, and government contract timing. The company’s prior quarter already showed strong top-line growth and positive operating cash flow, but also a large operating loss and slow 12-month RPO conversion at just 35%. The full-year revenue raise is incremental relative to the existing range, and the market appears to want clearer evidence of sustained margin improvement and reduced capital intensity. Overall, the earnings news is operationally positive but fails to resolve the key overhangs that have kept the stock volatile.

Implication

The Q2 beat and guidance raise confirm that demand for Planet's satellite imagery and analytics remains strong, particularly in defense and sovereign segments. However, the stock's muted reaction suggests the market remains focused on the dilution overhang from the ATM and the need for faster conversion of remaining performance obligations into revenue. Until Planet demonstrates sustained gross margin improvement and a reduction in capital intensity, the shares may continue to trade at a discount to growth expectations. Investors should monitor upcoming disclosures on renewals of major U.S. government contracts and any actual usage of the ATM program. If those signals turn positive and RPO conversion accelerates, the stock could re-rate; otherwise, the current WAIT stance and risk of multiple compression remain appropriate.

Thesis delta

The Q2 earnings beat and modest full-year guidance raise are positive developments that slightly improve the near-term revenue trajectory, but they do not fundamentally alter the core concerns from the master report. The stock's dip despite the beat indicates that the market continues to weigh dilution, backlog quality, and capital intensity more heavily than top-line growth. Therefore, while the operational momentum is intact, the investment thesis remains unchanged with a WAIT rating, and any upgrade would require evidence of improved RPO conversion, larger margin expansion, and disciplined capital allocation.